Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 149

Similar articles for PubMed (Select 20199686)


Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468.

Agelopoulos K, Greve B, Schmidt H, Pospisil H, Kurtz S, Bartkowiak K, Andreas A, Wieczorek M, Korsching E, Buerger H, Brandt B.

BMC Cancer. 2010 Mar 3;10:78. doi: 10.1186/1471-2407-10-78.


[Detection of breast cancer stem cells and the expression of key molecules in Hedgehog signaling pathway].

Lu ZH, Jia J, Ren J, Ma B, DI LJ, Song GH.

Beijing Da Xue Xue Bao. 2008 Oct 18;40(5):480-5. Chinese.


[Different coexisting genotypes in the breast cancer cell line MDA-MB-468].

Agelopoulos K, Schmidt H, Korsching E, Buerger H, Brandt B.

Pathologe. 2008 Nov;29 Suppl 2:333-7. doi: 10.1007/s00292-008-1021-3. German.


Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.

Uchino M, Kojima H, Wada K, Imada M, Onoda F, Satofuka H, Utsugi T, Murakami Y.

BMC Cancer. 2010 Aug 10;10:414. doi: 10.1186/1471-2407-10-414.


CD24 enhances DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells.

Ju JH, Jang K, Lee KM, Kim M, Kim J, Yi JY, Noh DY, Shin I.

Carcinogenesis. 2011 Oct;32(10):1474-83. doi: 10.1093/carcin/bgr173. Epub 2011 Jul 27.


Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA.

Cell Cycle. 2011 Nov 15;10(22):3871-85. doi: 10.4161/cc.10.22.17976. Epub 2011 Nov 15.


A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.

La Fleur L, Johansson AC, Roberg K.

PLoS One. 2012;7(9):e44071. doi: 10.1371/journal.pone.0044071. Epub 2012 Sep 25.


Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.

Tsunoda Y, Sakamoto M, Sawada T, Sasaki A, Yamamoto G, Tachikawa T.

Oncology. 2011;81(5-6):336-44. doi: 10.1159/000334690. Epub 2012 Jan 11.


CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.

Breast Cancer Res. 2006;8(5):R59.


Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA.

Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041. Epub 2010 May 12.


The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, Menendez JA.

Oncol Rep. 2011 Jan;25(1):135-40.


Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells.

Lin L, Hutzen B, Lee HF, Peng Z, Wang W, Zhao C, Lin HJ, Sun D, Li PK, Li C, Korkaya H, Wicha MS, Lin J.

PLoS One. 2013 Dec 23;8(12):e82821. doi: 10.1371/journal.pone.0082821. eCollection 2013.


Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.

Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB.

Int J Oncol. 2014 Sep;45(3):1193-9. doi: 10.3892/ijo.2014.2523. Epub 2014 Jun 25.


A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.

Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F.

Chin Med J (Engl). 2008 Oct 20;121(20):1980-6.


Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer.

Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C.

Neoplasia. 2009 Oct;11(10):987-1002.


Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.

Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A.

Cancer Res. 2008 Jul 15;68(14):5533-9. doi: 10.1158/0008-5472.CAN-07-5288.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk